ReferenceMetabolic & incretin research
Tirzepatide
LY3298176 · GIP/GLP-1 agonist · Mounjaro-class research peptide
Dual GIP/GLP-1 receptor agonist widely used as a reference incretin peptide in metabolic research.
About Tirzepatide
Tirzepatide is a dual agonist that engages both the GIP and GLP-1 receptors from a single fatty-acid-modified peptide backbone. It is a heavily cited reference compound in incretin and metabolic-receptor research. TagPep supplies tirzepatide as a research-use-only reference material with third-party analytical documentation.
Mechanism studied in research
Co-agonism of GIPR and GLP-1R, two incretin receptors studied together for their combined influence on insulin signaling and nutrient handling in model systems.
Areas of research investigation
- Incretin receptor co-agonism assays
- Glucose-metabolism model systems
- Receptor-binding and potency comparisons
- Formulation and stability research
Laboratory handling
Supplied lyophilized. Typical laboratory handling reconstitutes with bacteriostatic or sterile water, stores the working solution at 2–8 °C, and keeps the powder frozen and light-protected.
Comparisons
Tirzepatide research FAQ
Can I order tirzepatide for laboratory research?
Yes. TagPep stocks a 60 mg tirzepatide research vial with a batch-specific Certificate of Analysis. It is supplied for research use only and is not for human or veterinary use.
Why is tirzepatide called a dual agonist?
Because a single tirzepatide molecule activates two receptors — GIP and GLP-1 — a combination studied in metabolic research for its additive receptor effects.
Research use only. Tirzepatide is supplied as a laboratory reference material for in-vitro and research applications. It is not a drug, supplement or medical product, and is not intended for human or veterinary use, consumption, or clinical application.